ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Antiphospholipid antibodies"

  • Abstract Number: 012 • 2020 Pediatric Rheumatology Symposium

    Pediatric Antiphospholipid Syndrome: Clinical Features and Therapeutic Interventions in a Series of 22 Cases

    Jacqueline Madison1 and Jason Knight 1, 1University of Michigan, Ann Arbor

    Background/Purpose: Pediatric antiphospholipid syndrome (APS) is a thromboinflammatory disease classically defined by the presence of circulating antiphospholipid antibodies and either thrombotic events or pregnancy morbidity.…
  • Abstract Number: 142 • 2019 ACR/ARP Annual Meeting

    Antiphospholipid Antibodies Prevalence in Women with Late Pregnancy Complication and Low-Risk for Chromosomal Abnormalities

    Silvia Grazietta Foddai1, Massimo Radin 1, Elena Rubini 1, Irene Cecchi 1, Savino Sciascia 2, Dario Roccatello 1, Elisa Menegatti 1, Silvia Gaito 1, Luca Marozio 1, Tilde Manetta 1 and Giulio Mengozzi 1, 1University of Turin, Turin, Italy, 2Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy

    Background/Purpose: While current guidelines help defining correct pregnancy standard of care for patients with systemic lupus erythematosus andantiphospholipid syndrome (APS),little is known about the significance…
  • Abstract Number: 143 • 2019 ACR/ARP Annual Meeting

    Clinical and Genetic Factors Associated with Thrombosis or Pregnancy Morbidity of Antiphospholipid Antibody-Positive Systemic Lupus Erythematosus Patients

    Ji-Soong Kim1, Ga Young Ahn 2, Jeongim Choi 3, Jiyoung Lee 4, Youngho Park 1, So-Young Bang 1 and Sang-Cheol Bae 1, 1Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 2Guro Hospital, Korea University College of Medicine, Seoul, 3Busan St. Mary's Medical Center, Busan, 4Clinical Research Center for Rheumatoid Arthritis, Seoul

    Background/Purpose: Antiphospholipid syndrome (APS) is characterized by thromboembolic and obstetric morbidity associated with antiphospholipid antibodies (aPL) in systemic lupus erythematosus (SLE). This study aims to…
  • Abstract Number: 144 • 2019 ACR/ARP Annual Meeting

    Antiphospholipid Syndrome-Associated Preeclampsia Is Defined by a Distinct Clinical Phenotype

    Shashank Cheemalavagu1, Beth Wallace 2, Wendy Marder 3, Jason Knight 4 and Andrew Vreede 5, 1Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, 2Center for Clinical Management Research, VA Ann Arbor Healthcare System; Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, 3Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, 4Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, 5Division of Rheumatology, Department of Internal Medicine, Michigan Medicine; Rheumatology Section, VA Ann Arbor Health System, Ann Arbor, MI

    Background/Purpose: Antiphospholipid syndrome (APS) significantly increases risk of preeclampsia. It is assumed that APS is associated with a subset of severe preeclampsia, HELLP (Hemolysis; Elevated…
  • Abstract Number: 145 • 2019 ACR/ARP Annual Meeting

    Development of New International Classification Criteria for Antiphospholipid Syndrome: Phase II Results

    Medha Barbhaiya1, Stephane Zuily 2, Yasaman Ahmadzadeh 3, Raymond Naden 4, Karen Costenbader 5, Doruk Erkan 6 and On Behalf of the New APS Classification Criteria Collaborators 7, 1Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 2Centre Hospitalier Universitaire de Nancy, Nancy, France, 3N/A, Tehran, Iran, 4McMaster University, Hamilton, ON, Canada, 5Brigham and Women's Hospital, Boston, MA, 6Hospital for Special Surgery, New York City, 7Hospital for Special Surgery, New York, NY

    Background/Purpose: An international multi-disciplinary effort is underway to develop rigorous, new, consensus- and evidence-based classification criteria to identify patients with high likelihood of Antiphospholipid Syndrome…
  • Abstract Number: 305 • 2019 ACR/ARP Annual Meeting

    Naming Is Everything! the Cost of Inappropriate “Lupus Panel” Testing

    Caleb Anderson1, Roger Stitt 2 and Robert O'Brian 1, 1Walter Reed National Military Medical Center, Bethesda, MD, 2US Army, Ft Eustis

    Background/Purpose: Greater emphasis has been placed on cost saving measures due to ballooning healthcare cost in the U.S.  ACGME now evaluates trainee ability to practice…
  • Abstract Number: 660 • 2019 ACR/ARP Annual Meeting

    Antiphospholipid Syndrome (APS) in Systemic Lupus Erythematosus (SLE) Leads to a More Severe Disease

    Leyre Riancho-Zarrabeitia1, Víctor M Martinez-Taboada 2, Iñigo Rua Figueroa 3, Fernando Alonso 4, María Galindo 5, Juan Ovalles-Bonilla 6, Alejandro Olivé-Marqués 7, Antonio Fernández-Nebro 8, Jaime Calvo-Alen 9, Raul Menor Almagro 10, Eva Tomero-Muriel 11, Esther Uriarte Isacelaya 12, Alina Boteanu 13, Mariano Andrés 14, Mercedes Freire González 15, Gregorio Santos Soler 16, Esther Ruiz Lucea 17, Monica Ibañez Barcelo 18, Ivan Castellvi 19, Carles Galisteo 20, Víctor Quevedo Vila 21, Enrique Raya 22, Javier Narváez 23, Lorena Expósito 24, José A Hernández-Beriain 25, Loreto Horcada Rubio 26, Elena Aurrecoechea 27 and Jose Maria Pego-Reigosa 28, 1Hospital Sierrallana, Torrelavega, Spain, 2Hospital Valdecilla, Santander, 3Hospital Doctor Negrin, Las Palmas, 4Unidad Investigación SER, Madrid, Spain, 5Hospital 12 De Octubre, Madrid, 6Hospital Gregorio Marañón, Madrid, Spain, 7Hospital German Trias i Pujol, Badalona, Spain, 8Hospital Carlos Haya, Malaga, Spain, 9Hospital Universitario Araba, Vitoria-Gasteiz, Spain, 10Hospital Universitario de Jerez, Puerto De Santa María, Spain, 11Hospital Universitario La Princesa, Madrid, Spain, 12Hospital Universitario Donosti, San Sebastian, Spain, 13Hospital Universitario Ramón y Cajal, Madrid, Spain, 14Hospital General Universitario de Alicante, Alicante, Spain, 15Hospital Universitario Juan Canalejo, La Coruña, Spain, 16Hospital Marina Baixa, Villajoyosa, Spain, 17Hospital Universitario Basurto, Bilbao, Spain, 18Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, 19Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 20Hospital Parc Taulí, Barcelona, Catalonia, Spain, 21Hospital Comarcal Monforte, Monforteº, Spain, 22Hospital Universitario Clínico San Cecilio, Granada, Spain, 23Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, 24Hospital Universitario de Canarias, Las Palmas, Spain, 25Hospital Insular Universitario de Gran Canaria, Las Palmas, Spain, 26Complejo Hospitalario Universitario de Navarra, Pamplona, Spain, 27Rheumatology Department. Hospital Sierrallana, Torrelavega, Spain, 28Complexo Hospitalario Universitario, Vigo, Spain

    Background/Purpose: Antiphospholipid antibodies (aPL) have been associated with organ damage and certain features in SLE patients. Our aim was to investigate the differences between SLE…
  • Abstract Number: 128 • 2019 ACR/ARP Annual Meeting

    Metabolomics Analysis Identifies Biomarkers for APS and Suggests a Potential New Pathway Related to APS Pathogenesis

    Chun Li 1, Yu Zuo2, Jason Knight 3, Juan Feng 4, Xian Wang 4, David Karp 5 and Zhanguo Li 6, 1Peking Univerisity People's Hospital, Beijing, China (People's Republic), 2University of Texas Southwestern, Dallas, TX, 3Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, 4Peking University School of Basic Medical Science, Beijing, China (People's Republic), 5UTSouthwestern Medical Center, Dallas, TX, 6People's Hospital, Beijing University Medical School, Beijing, China (People's Republic)

    Background/Purpose: The metabolic disturbances that underlie antiphospholipid syndrome (APS) are currently unknown. The goal of this study was to utilize high-throughput metabolomics screening to identify…
  • Abstract Number: 1579 • 2019 ACR/ARP Annual Meeting

    Presence of Antiphospholipid Antibodies in Patients with SLE and Venous Thromboembolic Events of African American and Caucasian Race

    Elena Gkrouzman1, Julia Davis-Porada 1, Mary Peng 2 and Kyriakos Kirou 2, 1Hospital for Special Surgery, New York, 2Hospital for Special Surgery, New York, NY

    Background/Purpose: Risk of thrombosis is elevated in patients with systemic lupus erythematosus (SLE) compared to healthy individuals, especially during the first year after diagnosis. The…
  • Abstract Number: 129 • 2019 ACR/ARP Annual Meeting

    Surface Proteins on Exosomes Derived from Plasma of APS Patients Indicate an Altered Immune, Cell Adhesion and Coagulation Profile

    Ula Štok 1, Elizabeta blokar 1, Aleš Ambrožič 1, Matija Tomsic 1, Snezna Sodin-Semrl 2, Saša Čučnik 1 and Polona Žigon3, 1Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, 2Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, Ljubljana, Slovenia, 3Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana

    Background/Purpose: Antiphospholipid syndrome (APS) is characterized by thromboses and/or obstetric complications in presence of antiphospholipid antibodies (aPL). Extracellular vesicles have been suggested to play a…
  • Abstract Number: 1746 • 2019 ACR/ARP Annual Meeting

    Identifying Additional Risk Factors for Arterial and Venous Thrombosis Among Pediatric Antiphospholipid Antibodies Carriers

    Elizabeth Sloan1, Tracey Wright 1 and Yu Zuo 2, 1University of Texas Southwestern, Texas Scottish Rite Hospital for Children, Children's Health, Dallas, TX, 2University of Texas Southwestern, Dallas, TX

    Background/Purpose: Antiphospholipid antibodies (aPL) have been extensively reported in children; however, research on thrombotic risks associated with aPL among pediatric patients is scarce. Positive aPL…
  • Abstract Number: 130 • 2019 ACR/ARP Annual Meeting

    Is There Clinically Relevant Plasma Interference with ELISA Detection of APS Antibodies? Reproducibility of Serum and Plasma Testing in a Real-World Clinical Setting

    Michael Pham1, Giovanni Orsolini 2, Cynthia Crowson 3, Melissa Snyder 1, Rajiv Pruthi 4 and Kevin Moder 5, 1Mayo Clinic, Rochester, MN, 2University of Verona, Verona, Italy, 3Mayo Clinic Rochester, Rochester, 4Mayo Clinic, Rochester, 5Mayo Clinic Rochester, rochester, MN

    Background/Purpose: Traditionally in ELISA detection of APS antibodies, the use of serum is thought to be preferable over plasma according to international consensus bodies.  The…
  • Abstract Number: 1788 • 2019 ACR/ARP Annual Meeting

    Anti-neutrophil Extracellular Trap (NET) Autoantibodies in Primary Antiphospholipid Syndrome

    Yu Zuo1, Srilakshmi Yalavarthi 2, Kelsey Gockman 2, David Karp 3, Quan-Zhen Li 4 and Jason Knight 5, 1University of Texas Southwestern, Dallas, TX, 2University of Michigan, Ann Arbor, MI, 3UTSouthwestern Medical Center, Dallas, TX, 4Department of Immunology & Internal Medicine/University of Texas Southwestern Medical Center, Charleston, 5Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI

    Background/Purpose: Neutrophil extracellular traps (NETs) are prothrombotic tangles of chromatin and microbicidal proteins ejected from neutrophils in response to a variety of stimuli.  In antiphospholipid…
  • Abstract Number: 131 • 2019 ACR/ARP Annual Meeting

    Anti-Phosphatidylserine Prothrombin Antibodies as a Predictor of the LAC in an All-Comer Population

    Michael Pham1, Giovanni Orsolini 2, Cynthia Crowson 3, Melissa Snyder 1, Rajiv Pruthi 4 and Kevin Moder 5, 1Mayo Clinic, Rochester, MN, 2University of Verona, Verona, Italy, 3Mayo Clinic Rochester, Rochester, 4Mayo Clinic, Rochester, 5Mayo Clinic Rochester, rochester, MN

    Background/Purpose: Anti-phosphatidylserine prothrombin antibodies (aPS-PT) are reported to be highly associated with the LAC.  Some have suggested a clinically useful role for aPS-PT as a…
  • Abstract Number: 1791 • 2019 ACR/ARP Annual Meeting

    Antiphospholipid Antibody Profile Stability over Time: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Elena Gkrouzman1, Ecem Sevim 2, Jackie Finik 3, Danieli Andrade 4, Vittorio Pengo 5, Savino Sciascia 6, Maria Tektonidou 7, Amaia Ugarte 8, Cecilia Chighizola 9, H Michael Belmont 10, Laura Pérez Sánchez 11, Lanlan Ji 12, Paul Fortin 13, Maria Efthymiou 14, Guilherme De Jesus 15, David Branch 16, Cecilia Nalli 17, Michelle Petri 18, Ricard Cervera 19, Esther Rodriguez 20, Jason Knight 21, Tatsuya Atsumi 22, Rohan Willis 23, Maria Laura Bertolaccini 24, Hannah Cohen 14, Jacob Rand 25, Doruk Erkan 1 and On Behalf Of APS ACTION 26, 1Hospital for Special Surgery, New York City, 2Hospital for Special Surgery, New York, NY, 3Hospital for Special Surgery, New York, NY, New York, NY, 4Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil, 5Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, 6Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, 7First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, 8Hospital Universitario Cruces, University of the Basque Country Autoimmune Diseases Research Unit, Department of Internal M edicine, BioCruces Health, Biscay, Spain, 9Rheumatology, Istituto Auxologico Italiano, University of Milan, Milan, Italy, 10NYU Langone Health, New York, NY, 11IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 12Peking University First Hospital, Beijing, China (People's Republic), 13Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, 14University College London, London, United Kingdom, 15Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 16University of Utah Health Sciences Center, Salt Lake City, UT, 17Rheumatology and Clinical Immunology, Spedali Civili, Brescia, Italy, Brescia, Italy, 18Johns Hopkins University School of Medicine, Baltimore, MD, 19Hospital Clinic of Barcelona, Barcelona, Spain, 20Hospital Universitario 12 de Octubre, Madrid, Spain, 21Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, 22Hokkaido University, Sapporo, Japan, 23Antiphospholipid Standardization Laboratory, University of Texas Medical Branch, Galveston, TX, 24King's College London, London, United Kingdom, 25Weill Cornell Medicine, New York, 26APS ACTION, New York, NY

    Background/Purpose: APS ACTION "Registry" was created to study long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients with and without other systemic autoimmune diseases. Our primary…
  • 1
  • 2
  • 3
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology